)
Cephalon Inc. has filed a suit against Glenmark Pharmaceuticals Limited for alleged patent infringement of their cancer drug -Treanda.
On 26 December, the suit was filed in the US District Court for the District of Delaware seeking to prevent Glenmark from commercializing its abbreviated new drug application (ANDA) Bendamustine Hydrochloride product, generic version of Treanda.
Bendamustine, indicated for the treatment of patients with chronic lymphocytic leukemia, achieved sales of $659 million for the twelve-month period ending September 2013, according to IMS Health.
